Iowa Senate Bill SF2155

Iowa 2025-2026 Regular Session

• Introduced: 1/29/26
• Refer: 1/29/26

Caption

A bill for an act relating to schedule III controlled substances, and making penalties applicable.

Summary

Senate File 2155 would amend Iowa’s controlled substances schedule to add three specific drugs—misoprostol, mifepristone, and methotrexate—as Schedule III controlled substances. The bill’s stated purpose is to place these substances within the state’s controlled substances framework, which would subject their manufacture, distribution, or dispensing to the criminal penalties that apply to Schedule III drugs. Under the bill, a person who manufactures, distributes, or dispenses a Schedule III controlled substance would commit a class C felony and be subject to an additional fine of not less than $1,000 and not more than $50,000. The bill therefore expands the reach of Iowa’s drug control laws by explicitly naming these medications in statute and attaching felony-level penalties to conduct involving them.

Impact

SF 2155 would directly amend Iowa Code section 124.208 by adding a new subsection listing misoprostol, mifepristone, and methotrexate as Schedule III controlled substances. That change would affect how these medications are regulated under Iowa’s controlled substances laws and would expose manufacturers, distributors, and dispensers to the criminal penalties associated with Schedule III substances, including class C felony liability and mandatory fines. The bill would not merely regulate possession; it would target the commercial handling of the listed substances.

Sentiment

The available context shows limited formal debate or recorded votes, but the bill’s subject matter suggests a highly contentious policy area. Because the listed drugs are commonly associated with reproductive health and, in the case of methotrexate, also other medical uses, the proposal is likely to draw strong reactions from supporters of stricter drug regulation and opponents who view it as an attempt to criminalize access to widely used medications. The absence of committee transcript detail means the public record here does not show a consensus position, only that the bill advanced to subcommittee review.

Contention

The main point of contention is the bill’s decision to classify misoprostol, mifepristone, and methotrexate as controlled substances, which would be unusual for medications used in legitimate medical care. Critics are likely to argue that the measure could interfere with reproductive health care and other medical treatment, while supporters may frame it as a controlled-substances enforcement issue. The inclusion of methotrexate may also raise concern because it is used for conditions beyond abortion-related care, potentially broadening the bill’s practical impact beyond the reproductive health context.